Information  X 
Enter a valid email address

Xenetic Biosciences (XEN)

  Print      Mail a friend

Monday 30 April, 2012

Xenetic Biosciences

Directorate Changes

RNS Number : 2776C
Xenetic Biosciences PLC
30 April 2012
 

[30 April 2012]

Xenetic Biosciences plc

('Xenetic' or 'the Company')

Directorate Changes

 

Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological and vaccines and novel cancer drugs, announces that Igor Nikolaev has resigned from the board and that Dr Artur Isaev has been appointed as a Non Executive Director, both with immediate effect.

Artur Isaev, aged 41, graduated as a medical doctor in 1994 from Rostov Medical State University.  In 1998 he graduated from Plekhanov University of Economics with a degree in economics and finance and later that year obtained his MBA from the Moscow International Higher Business School.

In 1999, Dr Isaev was appointed General Director of audit and consulting group Mauer-Audit and Partners LLC.   In 2003 he founded the biotechnology company OJSC Human Stem Cells Institute (HSCI) - now a publicly-quoted company on Moscow's MICEX stock exchange - from which date he has held the position of General Director. HSCI engages in research and development as well as commercialization and marketing of innovative proprietary products and services in the areas of cell-based and gene and post-genome technologies.  He was also the founder of Gemabank, Russia's largest familial cord blood stem cell bank, and the current market leader. Gemabank was created in 2003 based at the Russian Oncology Centre's cryopreservation facilities in Moscow, and was one of the first in Russia.

Dr Isaev is a Vice President of the Russian Association of Regenerative Medicine and Cell Technologies.

 

In 2011 Dr Isaev was appointed to the Board of SynBio LLC, the Company's major shareholder and a key collaborative development partner. SynBio LLC holds 184,755,238 shares in the Company representing 45.297% of the Total Voting Rights.

Whilst Igor Nikolaev has relinquished his position as a Director, he has been appointed as an observer on the Xenetic board as an appointee of SYNBIO LLC, the Company's principal shareholder.

As a corollary to these changes, the composition of the undernoted Committees has been changed with immediate effect as noted below:

Remuneration Committee

Sir Brian Richards                            Chairman

Firdaus Dastoor                                Non Executive Director

Dr Dmitry Genkin                             Non Executive Director

 

Audit Committee

Sir Brian Richards                             Chairman

Firdaus Dastoor                                Non Executive Director

Dr Artur Isaev                                    Non Executive Director

 

Commenting on the Directorate Changes, M. Scott Maguire, CEO of Xenetic, said: "The Company is pleased to welcome Artur Isaev on to its Board and looks forward to having the benefit of his substantial commercial experience in the life sciences sector which we believe will contribute greatly to the clinical advancement of the Company's proprietary product pipeline."

Enquiries:

Xenetic Biosciences plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (NOMAD & Broker)

+44 (0)20 3205 7500

Claes Spång




Walbrook PR

+44 (0)20 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Paul Cornelius

paul.cornelius@walbrookir.com

 

Additional Information

Artur Aleksandrovich Isaev, aged 41, holds no shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Isaev appointment as a Director of the Company.

Current directorships/partnerships

Directorships/Partnerships in the last 5 years

Human Stem Cells Institute OJSC

Human Stem Cells Institute OJSC

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGURACUPPGCM